Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018)

References

• Verma M, Gupta SJ, Chaudhary A, et al. Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents – A brief review. Bioorg Chem. 2017;70:267–283.
   PubMed Web of Science ®Google Scholar
• Wang L-J, Jiang B, Wu N, et al. Natural and semisynthetic protein tyrosine phosphatase 1B (PTP1B) inhibitors as anti-diabetic agents. RSC Adv. 2015;5:48822–48834.
   Web of Science ®Google Scholar
• International Diabetes Federation. IDF Diabetes Atlas-7th Edition. DiabetesAtlas http://www.diabetesatlas.org/(2015).
   Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S13–S28.
   PubMed Web of Science ®Google Scholar
• Tamrakar AK, Maurya CK, Rai AK. PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011–2014). Expert Opin Ther Pat. 2014;24:1101–1115.
   PubMed Web of Science ®Google Scholar
• Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. Diabetes Care. 2016 Nov;39(11):2065–2079.
   PubMed Web of Science ®Google Scholar
• Mohler ML, He Y, Wu Z, et al. Recent and emerging anti-diabetes targets. Med Res Rev. 2009;29:125–195.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes 2019. Diabetes Care. 2019;42:S90–S102.
   PubMed Web of Science ®Google Scholar
• Barr AJ. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future Med Chem. 2010;2:1563–1576.
   PubMed Web of Science ®Google Scholar
• He Y, Yan H, Dong H, et al. Structural basis of interaction between protein tyrosine hosphatase PCP-2 and β-catenin. Sci China C Life Sci. 2005;48:163–167.
   PubMedGoogle Scholar
• Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem. 2009;16:706–733.
   PubMed Web of Science ®Google Scholar
• Haque A, Andersen JN, Salmeen A, et al. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell. 2011;30;147:185–198.
   Web of Science ®Google Scholar
• David B, Zongchao J, Nicholas KT, et al. Protein tyrosine phosphatases take off. Nat Struct Biol. 1995;2:1043–1053.
   PubMedGoogle Scholar
• Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497–503.
   PubMed Web of Science ®Google Scholar
• Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002;2:489–495.
   PubMed Web of Science ®Google Scholar
• Sobhia ME, Paul S, Shinde R, et al. Protein tyrosine phosphatase inhibitors: a patent review (2002-2011). Expert Opin Ther Pat. 2012;22:125–153.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang S, Yang Y, et al. Natural barrigenol–like triterpenoids: A comprehensive review of their contributions to medicinal chemistry. Phytochemistry. 2009;161:41–74.
   Google Scholar
• Xiong J, Wan J, Ding J, et al. Camellianols A-G, Barrigenol-like triterpenoids with PTP1B inhibitory effects from the endangered ornamental plant Camellia crapnelliana. J Nat Prod. 2017;80:2874–2882.
   PubMed Web of Science ®Google Scholar
• Hu J, Xiong J, Wan J inventor; Fudan University, China, assignee. Method for preparing barrigenol-like triterpenoid and its pharmaceutical application. patent CN108341849A; 2018.
   Google Scholar
• He H, Shi Y, Dai H, et al. inventor; Nantong University, China, assignee. Betulin derivative containing 5-phenyl-isoxazole as PTP1B inhibitor and its preparation. patent CN 106589046A; 2017.
   Google Scholar
• West BJ, Deng S, Uwaya A, et al. Iridoids are natural glycation inhibitors. Glycoconj J. 2016;33:671–681.
   PubMed Web of Science ®Google Scholar
• Qiu W, Zhou Y, Jiang L, et al. Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice. PLoS ONE. 7:e41391.
   PubMed Web of Science ®Google Scholar
• Fu L, Qi Y, Yang F, et al., inventor; Shanghai Jiao Tong University, China, assignee. Genipin derivative as protein tyrosine phosphatase 1B inhibitor and its preparation method. patent CN107382951A; 2017.
   Google Scholar
• Goswami SK, Gangadarappa SK, Vishwanath M, et al. Antioxidant potential and ability of phloroglucinol to decrease formation of advanced glycation end products increase efficacy of sildenafil in diabetes-induced sexual dysfunction of rats. Sex Med. 2016;4:e106–114.
   Web of Science ®Google Scholar
• Li L, Huang X, Han L, et al. inventor; Northeastern University, China, assignee. Phloroglucinol derivative isolated from seed of Syzygium cumini capable of inhibiting activity of PTP1B. patent CN 106916133A; 2017.
   Google Scholar
• Chagas VT, França LM, Malik S, et al. Paes, Syzygium cumini (L.) skeels: a prominent source of bioactive molecules against cardiometabolic diseases. Front Pharmacol. 2015;6:259–266.
   PubMed Web of Science ®Google Scholar
• Veigaa S, Leonellib E, Beelke M. Neuroactive steroids prevent peripheral myelinalterations induced by diabetes. Neurosci Lett. 2006;402:150–153.
   PubMed Web of Science ®Google Scholar
• Daisy P, Jasmine R, Ignacimuthu S, et al. A novel Steroid from Elephantopus scaber L. an Ethnomedicinal plant with antidiabetic. Phytomedicine. 2009;16:252–257.
   PubMed Web of Science ®Google Scholar
• Mao S, Feng M, Li J, et al. inventor; Nanchang University, China. assignee. Hypoglycemic composition and preparation method and application. patent CN107802626A; 2018.
   Google Scholar
• He H, Shi Y, Shi S, et al.,inventor; Nantong University, China, assignee. Lithocholic acid-3-oxime ester compound as PTP1B inhibitor and its preparation. CN107383146A; 2017.
   Google Scholar
• Zhang W, Sun P, Gong J, et al. inventor; The Second Military Medical University, China, assignee. Preparation of four-ring fused compounds as antitumor, antifungal, antibacterial, and antiinflammatory agents. patent WO 2015/124037A1.
   Google Scholar
• Hu CL, Xiong J, Gao LX. Diterpenoids from the shed trunk barks of the endangered plant Pinus dabeshanensis and their PTP1B inhibitory effects. RSC Adv. 2016;6:60467–60478.
   Web of Science ®Google Scholar
• Zhu F, Qin C, Tao L, et al. Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci US. 2011;108:12943–12948.
   PubMed Web of Science ®Google Scholar
• Park C, Lee JS. Mini Review: Natural ingredients for diabetes which are approved by Korean FDA. Biomed Res. 2013;24:164–169.
   Google Scholar
• Hu J, Hu C, Xiong J, et al. inventor; Fudan University, China, assignee. Pinus dabeshanensis bark extract and preparation method and pharmaceutical application thereof. patent CN107021942A; 2017.
   Google Scholar
• Hu J, Xiong J, Hong Z, et al., inventor; Fudan University, China, assignee. Phloroglucinol-abietane diterpene-series compound and its preparing method and application. patent CN105837592A; 2016.
   Google Scholar
• Xiong J, Hong ZL, Gao LX, et al. Chlorabietols A-C, Phloroglucinol-Diterpene adducts from the Chloranthaceae Plant Chloranthus oldhamii. J Org Chem. 2015;6(80):11080–11085.
   Google Scholar
• Hu J, Hu C, Xiong J, et al. inventor; Fudan University, China, assignee. Preparing of monocyclic diterpene compound of cassipourol. patent CN 107840814A; 2018.
   Google Scholar
• Liang Y, Li XM, Cui CM, et al. A new rearranged chamigrane sesquiterpene from Laurencia okamurai. Chin Chem Lett. 2009;20:190–192.
   Web of Science ®Google Scholar
• Yu XQ, He WF, Liu DQ. A seco-laurane sesquiterpene and related laurane derivatives from the red alga Laurencia okamurai Yamada. Phytochemistry. 2014;103:162–170.
   PubMed Web of Science ®Google Scholar
• Guo Y, Li J, Li X, et al., inventor; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, assignee. Process for preparation and application of algal sesquiterpene compound. patent CN 107176936A; 2017.
   Google Scholar
• Hu J, Hu C, Xiong J, inventor; Fudan University, Peop. Rep. China, assignee. Sesquiterpene spirolactone compound isolated from Abies benshazuensis as PTP1B inhibitor. patent CN 106957324A; 2017.
   Google Scholar
• He X, Bai Y, Zhao Z, et al. Local and traditional uses, phytochemistry, and pharmacology of Sophora japonica L.: A review. J Ethnopharmacol. 2016;187:160–182.
   PubMed Web of Science ®Google Scholar
• Ma Q, Wei R, Sang Z, et al., inventor; Nanyang Normal University, China, assignee. Naphthoquinone glucoside compound and its production method and application. patent CN 107501362A; 2017.
   Google Scholar
• Mao S, Li J, Guo Y, et al. inventor; Nanchang University, China. assignee. Application of α-tocopheryl quinone in medicines for treating diabetes or obesity. patent CN 104387253A; 2015.
   Google Scholar
• Mao S, Yang F, Zhang Y, et al., inventor; Nanchang University, China, assignee. Natural compound with hypoglycemic effect, and application thereof in preparing drug fortreating diabetes or obesity. patent CN 106748666A; 2017.
   Google Scholar
• Mao S, Tong L, Zhang Y, et al. inventor; Nanchang University, China. assignee. Dibenzyl-series natural compound with hypoglycemic activity and its application. patent CN 106748664A; 2017.
   Google Scholar
• Mao S, Zhang Y, Li J, et al., inventor; Nanchang University, China, assignee. Application of 3,5-dihydroxy-2-[3,7-dimethyl-2(trans),6-octadienyl]-biphenyl. CN 106580933A (2017).
   Google Scholar
• Garg A, Sharma A, Krishnamoorthy P, et al. Role of Niacin in Current Clinical Practice: A Systematic Review. Am J Med. 2017;130:173–187.
   PubMed Web of Science ®Google Scholar
• Reasner CA. Niaspan®: a powerful treatment option for ‘diabetic dyslipidaemia’. Eur Heart J Suppl. 2005;7:F48–F55.
   Web of Science ®Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of compounds containing nicotinic acid and nicotinamide structure useful as the PTP1B inhibitor in the treatment of type 2 diabetes. patent CN 104725306A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of nicotinamide derivative as PTP1B inhibitor for the treatment of type 2 diabetes. patent CN 104725307A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Protein tyrosine phosphatase 1B (PTP1B) inhibitor containing nicotinamide structure, preparation method and application for treating type II diabetes. patent CN 104725308A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing nicotinamide structure and application thereof for treating type 2 diabetes mellitus. patent CN 104725309A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of PTP1B inhibitors. patent CN 104725311A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of compound nicotinamide structure as PTP1B inhibitor for treating type 2 diabetes mellitus. patent CN 104725312A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of compounds containing niacinamide and piperidine structure as the PTP1B inhibitor in the treatment of type 2 diabetes. patent CN 104725353A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of compounds containing niacinamide and piperidine structure as PTP1B inhibitor for the treatment of type II diabetes. patent CN 104725354A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing niacinamide and piperidine structure and application thereof for treating type II diabetes mellitus. patent CN 104725355A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing nicotinamide structure and piperidine structure. patent CN104788424A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of PTP1B inhibitor containing nicotinamide structure and piperidine structure and their application as antidiabetic agents. patent CN 104788425A; 2015.
   Google Scholar
• Kaushik N, Kumar N, Kumar A. Synthesis, antioxidant and antidiabetic activity of 1-[(5-Substituted phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-5-phenyl-1H-tetrazole. Indian J Pharm Sci. 2016;78:352–359.
   Web of Science ®Google Scholar
• Katritzky AR, Jain R, Petrukhin R, et al. QSAR correlations of the algistatic activity of 5-amino-1-aryl-1H-tetrazoles. SAR QSAR Environ Res. 2001;12:259–266.
   PubMed Web of Science ®Google Scholar
• Omose YM, Aekawa TM, Daka HO, et al. Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem Pharm Bull. 2002;50:100–111.
   PubMed Web of Science ®Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of tetrazole compounds as PTP1B inhibitors. patent CN 104744386A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of tetrazole compounds as PTP1B inhibitors for treating. patent CN 104744387A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Tetrazole structure-containing PTP1B inhibitors, their preparation method and use. patent CN 104744388A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Tetrazolylpropanamide derivatives as PTP1B inhibitors and their preparation, pharmaceutical compositions and use in the treatment of non-insulin-dependent diabetes. patent CN 104803931A (2015).
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of tetrazole derivative as PTP1B inhibitor. patent CN 104803932A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of tetrazole compounds as PTP1B inhibitors for treating type 2 diabetes. patent CN 104803933A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Tetrazole-propanamide derivatives as PTP1B inhibitors and their preparation, pharmaceutical compositions and use in the treatment of non-insulin-dependent diabetes. patent CN 104803977A; 2015.
   Google Scholar
• Chhabria MT, Patel S, Modi P, et al. Thiazole: A review on chemistry, synthesis and therapeutic importance of its derivatives. Curr Top Med Chem. 2016;16:2841–2862.
   PubMed Web of Science ®Google Scholar
• Abdel-Sattar NEA, El-Naggar AM, Abdel-Mottaleb MSA. Novel thiazole derivatives of medicinal potential: synthesis and modeling. J Chem. 2017;1–11. Article ID 4102796.
   Google Scholar
• Khatik G, Datusalia AK, Ahsan W, et al. A retrospect Study on thiazole derivatives as the potential antidiabetic agents in drug discovery and developments. Curr Drug Discov Technol. 2018;15:163–177.
   PubMedGoogle Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of cyclopentadienyl compds. as PTP1B inhibitor for treating type 2 diabetes. patent CN 104744396A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Compound containing cyclopentadiene and cyanoaniline structure as PTP1B inhibitor for treating type 2 diabetes mellitus and its preparation. patent CN 104744397A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of PTP1B inhibitor containing cyclopentadiene and aniline structure. patent CN 104803937A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of cyclopentadiene compounds as PTP1B inhibitors for treating non-insulin-dependent diabetes. patent CN 104803941A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Aniline-thiazole-cyclopentadiene-acetamide as PTP1B inhibitor and their preparation. patent CN 104803944A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of PTP1B inhibitor containing cyclopentadiene structure and their application as antidiabetic agents. patent CN 104803942A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing cyclopentadiene structure and thioaniline structure, and preparing method and application thereof. patent CN 104803943A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing cyclopentadiene and aniline structure and application. patent CN104829552A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of halophenyl thiazole and cyclopentadiene compounds as PTP1B inhibitor for treating type 2 diabetes. patent CN 104744398A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing cyclopentadiene structure and phenyl thiazole structure its preparation. patent CN 104803938A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of cyclopentadiene and nitrophenylthiazole containing PTP1B inhibitors. patentCN 104803939A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. Preparation of N-[3-[(dimethylamino)phenyl]-2-thiazolyl] [(dimethylamino)phenyl]methyl]cyclopentadiene-1-acetamide derivatives as PTP1B inhibitor useful for the treatment of type II diabetes. patent CN 104803940A; 2015.
   Google Scholar
• Cai Z, inventor; Foshan Saiweisi Medicine Science & Technology Co Ltd, assignee. PTP1B inhibitor containing cyclopentadiene structure and phenyl aniline structure, and application thereof. patent CN 104803945A; 2015.
   Google Scholar
• Sravanthi TV, Manju SL. Indoles-A promising scaffold for drug development. Eur J Pharm Sci. 2016;91:1–10.
   PubMed Web of Science ®Google Scholar
• Morse GD, Reichman RC, Fischl MA, et al. Concentration-targeted phase I trials of Atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antivir Res. 2000;45:47–58.
   PubMed Web of Science ®Google Scholar
• Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53:417–450.
   PubMed Web of Science ®Google Scholar
• Isaac MT. Review: combining pindolol with an SSRI improves early outcomes in people with depression. Evid Based Ment Health. 2004;7:107–130.
   PubMedGoogle Scholar
• Lednicer D. The organic chemistry of drug synthesis-A. 7. NJ, USA: John Wiley & Sons; 2007. p. 141–154.
   Google Scholar
• Witjes JA, Kolli PS. Apaziquone for non-muscle invasive bladder cancer: a critical review.Expert. Opin Invest Drugs. 2008;17:1085–1096.
   Google Scholar
• Leneva IA, Russell RJ, Boriskin, et al. Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of Arbidol. Antivir Res. 2009;81:132–140.
   PubMed Web of Science ®Google Scholar
• Prince HM, Panobinostat BM. (LBH589): a novel pan-deacetylase inhibitor with activity in T cell lymphoma. Hematol Meeting Rep. 2009;3: 33–38. (Parkville, Australia: Peter MacCallum Cancer Centre and University of Melbourne).
   Google Scholar
• Hu W, Jing C, Xiao G, et al. inventor; Normal East China University, assignee. Chiral 3,3-disubstituted oxoindole derivatives as protein tyrosine phosphatase 1B inhibitors and their preparation, pharmaceutical compositions and use in the treatment of obesity and diabetes. patent CN 104693092A; 2015.
   Google Scholar
• Wang W, Li J, Feng B, et al. inventor; Jiangnan University,Shanghai Institute of Materia Medica, assignee. 2,3-Dihydroperimidine analogs and synthetic method, pharmaceutical composition and use thereof. patent CN 104418811A; 2015.
   Google Scholar
• Shi D, Li X, Wang L, et al., inventor; Institute of Oceanology, Chinese Academy of Sciences, assignee. Process for preparation of oxadiazole compounds and application in preparing medicine for preventing and/or treating type 2 diabetes. CN 106632130A; 2017.
   Google Scholar
• Shi D, Li X, Wang L, et al. inventor; assignee. Preparation of Bromophenol-oxazole Z compounds as PTP1B inhibitors for treating type 2 diabetes. patent CN 106588806A; 2017.
   Google Scholar
• Han J inventor; Heilongjiang Chinese Medicine University, assignee. Process for preparation of medicine for preventing and treating diabetes mellitus. patent CN108218861A; 2018.
   Google Scholar
• Liu Z, Zheng S, Qian J, et al. inventor; Zhejiang Gelusite Biology Tech Co Ltd, assignee. Preparation method of (1,2-dimethylallyl)chalcone compounds useful as PTP1B inhibitors for the treatment of diabetes. patent CN 108586388A; 2018.
   Google Scholar
• Xue W, Tian J, Wang XS, et al. Discovery of potent PTP1B inhibitors via structure-based drug design, synthesis and in vitro bioassay of Norathyriol derivatives. Bioorg Chem. 2019;86:224–234.
   PubMed Web of Science ®Google Scholar
• Liu G. Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges. Curr Med Chem. 2003;10:1407–1421.
   PubMed Web of Science ®Google Scholar
• Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov. 2002;1:696–709.
   PubMed Web of Science ®Google Scholar
• Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med. 2013;126:S10–20.
   PubMed Web of Science ®Google Scholar